Miscellaneous Quiz / Dementia Drugs

Random Miscellaneous Quiz

QUIZ: Can you name the Dementia Drugs?

Quiz not verified by Sporcle

Forced Order
Also try: The First Ten...
Challenge
Share
Tweet
Embed
Score 0/25 Timer 20:00
HintAnswer
P-kinetics: Metabolized by cholinesterase at CNS sites
SE: GI
1st drug for improving cognitive s/s in AD. Reduces deterioration in cognitive performance (MMSE & CGIC) in the first 3 mo - no evidence it delays long term course of AD
Rivastigimine class
Tacrine class
SE: Mostly GI - available in patch with less side effects.
P-kinetics: Once daily dosing, 100% oral bioavailability. Metabolism by cytochrome p450
SE: Higher CNS affinity --> less PNS side effects
Clinical efficacy similar to donepezil and tacrine
P-kinetics: Partial hepatic metabolism (not p450 - few rx interactions). T1/2 = 60-80 hrs, clearance decreased in alkaline & increased in acidic urine. ER formulation available.
Galantamine class
Use: Mild to moderate AD & mild to moderate dementia in Parkinson's dz. In phase III trials for Lewy Body dementia & mild cognitive impairment
P-kinetics: Multiple daily dosages & a slow dosage titration to limit GI side effects. Partial metabolism via CYP450, renal excretion.
HintAnswer
Donepezil class
SE: Many. Hepatotoxic -- not drug of choice
SE: Tolerated well - side effect frequency similar to placebo
P-kinetics: Poor oral bioavailability
Inhibits AChE. Increases effect of remaining cholinergic afferents. May reduce A-beta 1-42 by stimulating Ab production. May help control some behavioral symptoms.
Use: Symptom management in mild, moderate, & severe AD. Improves global function, cognition, behavior, and delays time to institutionalization. Does not alter long term prognosis.
Use: Mild to moderate AD (viable 1st line tx). May also be beneficial in treating s/s of vascular dementia & dementia w/ Lewy Bodies
Effect: Improved cognitive & psychomotor function. Reduction on care dependence. Neuroprotective - slows dz progression
Use: Moderate to severe AD. Pending approval for mild AD. In trials for moderate vascular dementia
MOA: NMDA receptor antagonist (use-dependent, non-competitive)
Long-acting AChE inhibitor, muscarinic modulator & nicotinic agonist, also may be MAOI, decreases GABA release, increases release of NE, DA, 5-HT
Natural alkaloid derived from daffodil

You're not logged in!

Compare scores with friends on all Sporcle quizzes.
Sign Up with Email
OR
Log In

You Might Also Like...

Show Comments

Extras

Top Quizzes Today


Score Distribution

Your Account Isn't Verified!

In order to create a playlist on Sporcle, you need to verify the email address you used during registration. Go to your Sporcle Settings to finish the process.